EAN/PNS* guideline on diagnosis and treatment of CIDP “strongly recommends” SCIg for CIDP maintenance19

Watch Dr. Peter Van den Bergh, lead author, take you through the EAN/PNS guideline highlights.

For adults with CIDP stabilized on IVIg


Greater Freedom for Everyday Living

Hizentra is indicated for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.

-Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.

Discover the latest innovation in Ig

Hizentra is the first and only Ig available in prefilled syringes

Hizentra may help your CIDP patients address challenges with IVIg

Clinical challenges icon

Clinical challenges in CIDP:

  • In some patients, poor venous access can make IV infusion difficult1
  • Systemic adverse reactions, such as headache and fever, can occur2
Lifestyle burdens icon

Lifestyle burdens in CIDP:

  • IV infusions can be costly and constraining3
  • Travel to an infusion clinic can be time-consuming and require missing work3

*Based on equivalent dosing in grams. Hizentra may be administered in 1 or 2 infusions over 1 or 2 consecutive days.

Hizentra is:

  • A 20% immunoglobulin, half the volume of 10% IVIg*
  • Infused in smaller doses more frequently than IVIg
  • Subcutaneous, so no need to find a vein
Hizentra Volume icon

Hizentra can be:

  • Conveniently self-administered, allowing patients to infuse at an appropriate place and time
  • Infused in a median time of ~1 hour per infusion
  • Adjusted to meet patient needs, with 2 safe and effective dosing options
Self-administration Time icon

Consider Hizentra for patients with CIDP who:

Hizentra Patient: James

Experience IV-Related systemic adverse reactions

Hizentra Patient: Alice

Have venous access issues

Clinical Challenges

Hizentra Patient: Miguel

Require more frequent IV infusions

Hizentra Patient: Allison

Seek flexibiltiy, freedom, and control

Lifestyle Burdens

Photos do not depict actual patients

Watch Dr. Peter Van den Bergh, lead author, take you through the EAN/PNS guideline highlights

Learn about support services

Below are areas you may find especially helpful when providing Hizentra to your patients.

Voluntary withdrawal of specific Hizentra vial lots.

For more information click here

View information about Hizentra for:


chronic inflammatory demyelinating polyneuropathy


primary immunodeficiency

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

You are now leaving the current website.

Do you want to continue?

No Yes